Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of “Hold” by Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has been given a consensus rating of “Hold” by the seven brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $22.50.

DCTH has been the topic of a number of research reports. Zacks Research cut shares of Delcath Systems from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Wall Street Zen cut shares of Delcath Systems from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings raised shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Evercore set a $27.00 price target on shares of Delcath Systems in a report on Thursday, February 26th. Finally, BTIG Research lowered their price target on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, February 26th.

Institutional Investors Weigh In On Delcath Systems

A number of hedge funds have recently modified their holdings of DCTH. California State Teachers Retirement System bought a new stake in shares of Delcath Systems in the 2nd quarter worth approximately $26,000. Russell Investments Group Ltd. bought a new stake in Delcath Systems during the 3rd quarter valued at $29,000. Tower Research Capital LLC TRC bought a new stake in Delcath Systems during the 2nd quarter valued at $40,000. Legal & General Group Plc bought a new stake in Delcath Systems during the 2nd quarter valued at $46,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Delcath Systems during the 2nd quarter valued at $151,000. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Up 3.5%

Shares of NASDAQ DCTH opened at $11.23 on Friday. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $18.19. The stock’s 50 day moving average price is $10.24 and its 200-day moving average price is $9.87. The company has a market capitalization of $387.66 million, a PE ratio of 1,123.00 and a beta of 0.54.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. The company had revenue of $24.99 million for the quarter, compared to analysts’ expectations of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. As a group, research analysts expect that Delcath Systems will post -0.88 EPS for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.